Innoviva (INVA) Operating Margin Growth (5y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 54,878.00 |
| Dec 31, 2025 | 635.00 |
| Sep 30, 2025 | -6,312.00 |
| Jun 30, 2025 | -4,739.00 |
| Mar 31, 2025 | -5,000.00 |
| Dec 31, 2024 | -95,029.00 |
| Sep 30, 2024 | -4,415.00 |
| Jun 30, 2024 | -3,848.00 |
| Mar 31, 2024 | -115,334.00 |
| Dec 31, 2023 | -52,719.00 |
| Sep 30, 2023 | 3,431.00 |
| Jun 30, 2023 | -107,598.00 |
| Mar 31, 2023 | -150,307.00 |
| Dec 31, 2022 | -107,821.00 |
| Sep 30, 2022 | -8,189.00 |
| Jun 30, 2022 | -57,132.00 |
| Mar 31, 2022 | -78,242.00 |
| Dec 31, 2021 | -69,788.00 |
| Sep 30, 2021 | 1,280.00 |
| Jun 30, 2021 | 818,572.00 |
| Mar 31, 2021 | -58,237.00 |
| Dec 31, 2020 | -135,608.00 |
| Sep 30, 2020 | 3,300.00 |
| Jun 30, 2020 | 4,806.00 |
| Mar 31, 2020 | 8,594.00 |
| Dec 31, 2019 | 9,514.00 |
| Sep 30, 2019 | 104,761.00 |
| Jun 30, 2019 | 114,183.00 |
| Mar 31, 2019 | 198,210.00 |
| Dec 31, 2018 | 60,023.00 |
| Sep 30, 2018 | 195,059.00 |
| Jun 30, 2018 | 61,521.00 |
| Mar 31, 2018 | 260,318.00 |
| Dec 31, 2017 | 6,165.00 |
| Sep 30, 2017 | 241,444.00 |
| Jun 30, 2017 | 690,940.00 |
| Mar 31, 2017 | 407.00 |
| Dec 31, 2016 | 74,982.00 |
| Sep 30, 2016 | 53,790.00 |
| Jun 30, 2016 | 44,997.00 |
| Mar 31, 2016 | 40,899.00 |